NuVasive should report strong Q4 results, says Needham Needham expects NuVasive to report very good Q4 results, but the firm thinks that most investors also expect the company to report strong results. Needham thinks it is becoming more difficult for the company to beat expectations, but it still expects estimates for the company to rise, and it keeps a Buy rating on the stock.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.